List view / Grid view

Prostate cancer


Panacea initiates Phase I prostate cancer vaccine therapy trial

19 January 2017 | By Niamh Marriott, Digital Editor

Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…